Hetero launches generic bevacizumab in India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Hetero launched a biosimilar of bevacizumab in India for the treatment of metastatic colorectal cancer under the brand name Cizumab.

The product has been approved by the drug controller general of India and has been recommended as a first-line treatment for mCRC. The product will be made available to patients in a single dose vial with two strengths, 100 mg and 400 mg. It will be marketed and distributed by Hetero Healthcare Ltd.

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login